AnaptysBio Inc Stock
AnaptysBio Inc Stock
There is an upward development for AnaptysBio Inc compared to yesterday, with an increase of €1.40 (2.890%).
With 26 Buy predictions and not a single Sell prediction AnaptysBio Inc is an absolute favorite of our community.
As a result the target price of 62 € shows a positive potential of 24.5% compared to the current price of 49.8 € for AnaptysBio Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for AnaptysBio Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | 2.890% | -11.071% | 6.867% | 186.207% | 15.814% | 152.792% | 167.742% |
| Immunic Inc. | -0.800% | -10.307% | 9.372% | -3.502% | 130.698% | -27.565% | -92.955% |
| Ocuphire Pharma Inc. | -4.560% | 0.127% | 6.199% | 371.292% | 134.245% | -4.253% | - |
| NanoViricides Inc. | -0.630% | -0.625% | -2.454% | -23.558% | -14.516% | -24.501% | -79.584% |
Comments
AnaptysBio (ANAB) had its price target raised by Piper Sandler from $67.00 to $95.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (ANAB) had its price target raised by UBS Group AG from $70.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
News
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally
On Dec. 23, AnaptysBio (NASDAQ:ANAB) Director J. Anthony Ware executed an open-market sale of 3,900 shares for a transaction value of $193,342.50, representing 28.82% of his direct holdings
What Investors Should Know About a $163K AnaptysBio Insider Sale
Paul F. Lizzul, the chief medical officer of AnaptysBio (NASDAQ:ANAB), reported the direct sale of 3,650 shares of the company for a total consideration of approximately $163,191.50 on Thursday, as